This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celsion Corporation Initiates Development Program For Glioblastoma Brain Tumors With ThermoDoxA® And HIFU

LAWRENCEVILLE, N.J., Jan. 21, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that the company is formalizing a program to pursue the development of ThermoDox® to investigate applications for treating brain cancer tumors, notably Glioblastoma Multiforme or GBM. In addition to jointly submitting multiple grant applications, the company is also pursuing preclinical studies in collaboration with Dr. Costas D. Arvanitis at the Brigham and Women's Hospital and Harvard Medical School.  Experiments will study the use of ThermoDox in combination with MR guided High Intensity Focused Ultrasound (HIFU) to treat brain tumors, initially in animal models. 

"Brain cancer tumors represent a very high unmet medical need, and researchers have been pursuing applications with HIFU for many years," said Nicholas Borys, MD, Celsion's Chief Medical Officer.  "We are excited to investigate the addition of ThermoDox, our heat-activated liposomal encapsulation of doxorubicin, which could provide some clinical benefit for a population that desperately needs more applications."

Dr. Arvanitis, research fellow at Brigham and Women's Hospital and Harvard Medical School stated, "We have investigated the use of MR-guided focused ultrasound to treat brain tumors for many years and have identified the need for drugs that will improve our ability to treat brain tumors. We are excited about this drug design, which is positioned to work with heat and specifically HIFU, and its potential to cross the blood-brain barrier and potentially demonstrate drug concentration in ways that other drugs cannot. We are grateful for Celsion's support in this research and look forward to pursuing this initial, pre-clinical research with the hope of bringing this application to the clinic in the future."

About Glioblastoma Multiforme (GBM) Brain Tumors

Glioblastoma multiforme (GBM), WHO classification name "glioblastoma", is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for over 50% of all functional tissue brain tumor cases and nearly 20% of all intracranial tumors.  In 2013, projected US incidence of brain tumors approaches 23,000 cases, with projected mortality at 14,000. Treatment can involve chemotherapy, radiation and surgery. Median survival with standard-of-care radiation and chemotherapy is normally 15 months, and  Median survival without treatment is approximately 4½ months.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs